Clinical Trial Search

Primary: Baseline-adjusted Cmax of PTH(1-84) — 295.662; 330.820; 175.468; 99.708 Picogram per milliliter (pg/mL)

Primary: Maximum Observed Concentration (Cmax) of UPB-101 — 11.6; 24.4; 35.1; 34.9 ug/mL

Primary: Total Body Water — 1.85 liter

Primary: Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1) — 182; 794; 1540; 176 ng/mL

Primary: Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From Baseline — 9.02; 48.53; 70.95; 81.62 Percentage of Reduction

Primary: SRD Part - Number of Subjects With Drug-related Adverse Events — 0; 0; 0; 0 Participants

Primary: Number of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) — 1; 0; 2; 1 Participants

Primary: Percentage of Subjects With Drug-related Adverse Events — 22.2; 33.3; 0.0; 0.0 Percentage of subjects

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs , and TEAEs Leading to Participant Discontinuation From Study — 0; 3; 0; 0…

Primary: Maximum Observed Plasma Concentration (Cmax) — 456; 483 nanogram per millileter (ng/mL)

Primary: Geometric Mean Fold Rise (GMFR) From Baseline in Antibody Level — 4.4; 0.9 Ratio

Primary: Percentage (%) of Subjects With Drug-related Adverse Events (AEs) — 13.3; 9.1; 36.4; 57.9 Percentage of Participants

Primary: Number of Participants With Solicited Injection Site and Systemic Adverse Events — 1; 2; 1; 3 participants

Primary: Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib — 1423; 3806; 6569 ng*hr/mL

Primary: Part 1:Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Last Measurable Concentration (AUC[0-t]) and AUC From Zero Hours Extrapolated to Infinity AUC…

Primary: Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY2484595 — 12200; 17800; 17800 hours times nanograms per milliliter

Primary: Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs During the Single-Dose (SD) Period — 0; 0; 0; 0 participants

Primary: Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1 — 7.6; 0.0; 5.9; 0.0 Percentage of participants

Primary: Number of Subjects With Drug-Related Adverse Events (AEs) — 1; 0; 0; 0 Participants

Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 5.6 Percentage of participants

Primary: Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) — 0; 1; 0; 0 Participants

Primary: Rate of Iron Excretion. — 1.07; 1.69; 1.08 milligrams per day — p=< 0.05

Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 25; 0; 16.7; 0 Percentage of participants

Primary: Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection — 90.1; 82.5 Percentage of participants

Primary: The Amounts of Radioactivity Excreted in Urine and Faeces — 78.0; 6.08; 84.1 percentage of administered dose

Primary: Number of Participants With Investigator Defined Drug-related Adverse Events — 2; 1; 4; 2 Participants

Primary: Number of Subjects With Drug-related Adverse Events (AEs) — 0; 0; 0; 0 Participants

Primary: AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose for TAK-536 in Dry Syrup Cohort — 7065.6; 7341.2 nanogram*hour per milliliter…

Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) — 2070; 3740 hours*nanomoles/Liter…

Primary: Peak Plasma Concentration (Cmax) of Icatibant and Metabolites — 1190; 340; 365 ng/mL